Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025 Financial Highlights Total ...
Kuros Biosciences Ltd (CSBTF) reports a landmark year with 72% revenue growth, first-time profitability, and strategic advancements despite facing external challenges.
Earnings call Kuros Biosciences posted FY25 revenue of $146.1M (+72% YoY), adjusted EBITDA of $19.6M (13.4% margin), and first-ever net profit of $2.6M, exceeding guidance. Management guides for at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results